Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 6/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 6/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 6/20 | 1.00 |
| ▸ | CHRNB3 | Q05901 | 6/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 5/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7372710 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL12214039 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL676032 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| Hydrochloric Acid SCHEMBL7839221 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL8435491 | 0.96 | CHRNB2 (0.92) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL8438369 | 0.96 | CHRNB2 (0.92) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| Hydrochloric Acid SCHEMBL7406679 | 0.94 | CHRNB2 (0.90) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL13424978 | 0.93 | CHRNA3 (0.86) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL905202 | 0.93 | CHRNA3 (0.86) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 | |
| SCHEMBL30820824 | 0.93 | CHRNA3 (0.86) | CHRNB2CHRNB1CHRNB4CHRNA3CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4281056-A1 | COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION- RELATED DYSFUNCTION EXISTS | Alto Neuroscience, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2022159629-A1 | COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION- RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220226331-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220062252-A1 | CYCLOOXYGENASE INHIBITOR AND CALCIUM CHANNEL ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN UROLOGICAL PROCEDURES | OMEROS CORP (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | CHRNB2 11/4885CHRNB1 34/4885CHRNB4 15/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | CHRNB2 2238/4885CHRNB1 1444/4885CHRNB4 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.